FDA Approves Cilta-Cel for Treatment of Relapsed, Refractory Multiple Myeloma

The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.

Related Keywords

Binod Dhakal ,Janssen Research Development ,Division Of Hematology ,Janssen Biotech Inc ,Oncologic Drugs Advisory Committee ,Johnson ,College Of Wisconsin ,Janssen Biotech ,Postmodern Studio ,Drugs Advisory Committee ,Study Comparing ,Versus Pomalidomide ,Participants With Relapsed ,Lenalidomide Refractory Multiple Myeloma ,Janssen Research ,Medical College ,Jordan Schecter ,Innovative Medicine ,Targeted Treatment Approved ,Refractory Multiple Myeloma Who Have Received ,Least One Prior Line ,Standard Care ,Lenalidomide Refractory Multiple ,